ASX:ENPPharmaceuticals, Biotechnology & Life SciencesPharmaceuticals
Entropy Neurodynamics Ltd
$0.033
Day Range
$0.032 – $0.033
52 Week Range
$0.025 – $0.046
Volume
452.39K
Avg Volume (10D)
1.13M
Market Cap
$53.85M
Price Chart
Market Statistics
Open$0.032
Previous Close$0.033
Day High$0.033
Day Low$0.032
52 Week High$0.046
52 Week Low$0.025
Valuation
Market Cap53.85M
Shares Outstanding1.63B
Price to Book6.68
Trading Activity
Volume452.39K
Value Traded14.58K
Bid$0.032 × 287,137
Ask$0.033 × 135,261
Performance
1 Day3.13%
5 Day-2.94%
13 Week-5.71%
52 Week3.13%
YTD0.00%
Technical Indicators
RSI (14)45.62
50-Day SMA$0.033
200-Day SMA$0.034
Latest News
Biotechnology
Entropy Neurodynamics Reports Breakthrough Results from Phase 2a TRP-8802 Study for Treating IBS
Entropy Neurodynamics announces Phase 2a TRP-8802 IBS results: 75% responders, clear gut-brain axis effect; de-risks program ahead of TRP-8803 trials.
Biotechnology
Entropy Neurodynamics' TRP-8803 Trial Shows Repeatable Psychedelic Effects in BED Study
Entropy Neurodynamics reports repeatable psychedelic effects in TRP-8803 BED trial; Cohort 2 enrollment advancing; R&D incentives boost cash runway.
Biotechnology
Entropy Neurodynamics Granted Australian Patent for TRP8803 to Treat Chronic Pain and Psychiatric Conditions
Entropy Neurodynamics (ASX: ENP) granted Australian patent for TRP8803 (IV psilocybin) for chronic pain and neuropsychiatric disorders; protection to 2042.